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Intravenous iron administration induces oxidation of serum al-
bumin in hemodialysis patients.
Background. Intravenous iron administration (IVIR) is ef-
fective for correcting anemia in hemodialysis (HD) patients.
However, it may also enhance the generation of hydroxyl rad-
icals. Recently, plasma proteins have been demonstrated to be
extremely susceptible to oxidative stress. Therefore, we inves-
tigated the effect of IVIR on the oxidative status of albumin, a
major plasma protein, in HD patients.
Methods. Eleven hemodialysis (HD) patients were treated
with 40 mg of saccharated ferric oxide intravenously after every
dialysis session for four weeks, and 11 age-/gender-matched HD
patients were treated with vehicle. We performed high perfor-
mance liquid chromatography (HPLC) analysis of serum albu-
min and determined the levels of reduced and oxidized albumin.
Carbonyl formation of plasma proteins were also measured us-
ing an anti-2,4 dinitrophenylhydrazine antibody in patients with
or without IVIR.
Results. IVIR resulted in an increase in both disulfide form
(f(HNA-1)) and oxidized form (f(HNA-2)) of albumin in HD
patients (36.0 ± 6.03 vs. 41.7 ± 6.27; 5.46 ± 1.50 vs. 8.7 ±
2.22, respectively, P < 0.05). The findings here also show that
IVIR substantially increased plasma protein carbonyl content
by oxidizing albumin. In addition, we found a strong correlation
between plasma carbonyl content and the levels of oxidized al-
bumin (f(HNA-1) and f(HNA-2)) in HD patients (R = 0.674
and R = 0.724, respectively, P < 0.01).
Conclusion. The results of this study indicate that the HPLC
analysis of serum albumin represents a potentially useful
method for the quantitative and qualitative evaluation of oxida-
tive stress in HD patients, and strongly suggest the possibility
that oxidative stress, generated by IVIR, enhances the oxidation
of albumin in those patients.
1These two authors contributed equally to this work.
Key words: albumin, oxidative stress, hemodialysis, saccharated ferric
oxide.
Received for publication August 21, 2003
and in revised form December 29, 2003, and February 2, 2004
Accepted for publication March 10, 2004
C© 2004 by the International Society of Nephrology
Oxidative stress has long been incriminated in the de-
velopment of dialysis-related pathologic conditions, such
as b 2-microgloblin amyloid arthropathy and accelerated
atherosclerosis [1]. Until recently, direct evidence for in
vivo oxidative stress in HD patients relied almost entirely
on the measurement of lipid peroxidation by-products
such as malondialdehyde (MDA) and thiobarbituric acid-
reactive substances (TBARS)[2]. Despite the fact that
proteins are extremely susceptible to oxidative stress, re-
ports on the detection of oxidatively modified proteins
have not been extensive. However, the measurement of
the markers for protein oxidation, such as advanced pro-
tein oxidation products (AOPP) or carbonyl contents, has
recently been applied to assess the oxidative stress in the
pathologic conditions. In 2001, Himmelfarb et al [3] re-
ported for the first time that the oxidation of albumin
accounts for almost all of the excess plasma protein oxi-
dation in uremic patients as evidenced by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
and an immunoassay using an anti-2,4 dinitrophenylhy-
drazine (DNP) antibody developed by Shacter et al [4,
5]. Human serum albumin (HSA) is a mixture of mer-
captalbumin (HMA; reduced form) and nonmercaptal-
bumin (HNA; oxidized form) [6, 7]. HMA contains one
highly reactive sulfhydryl group at position 34 (Cys-34),
while other serum proteins have little or none [8]. HNA
is composed of at least three types of molecules. The ma-
jor HNA component is a mixed disulfide with cysteine or
glutathione (HNA(Cys) or HNA(Glut))[6, 7]. The other
is a more highly oxidized product than the mixed disul-
fide, such as sulfenic (−SOH), sulfinic (−SO2H) and sul-
fonic (−SO3H) states (HNA(Oxi)), the proportions of
which are extremely small in extracellular fluids [9–11].
The high-performance liquid chromatography (HPLC)
analysis of albumin developed by Sogami et al permits
the clear separation of HSA into HMA and HNA [6],
and is used for the determination of the redox state for
various pathophysiologic conditions [12–15].
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Anemia is a major complication in HD patients, and
because of this, most patients routinely receive iron intra-
venously (IVIR) for anemia correction. Although IVIR
has been shown to improve both survival and quality of
life of HD patients [16–18], it has been suggested that
IVIR may enhance the generation of hydroxyl radicals in
the body through the inflammation process and the Fen-
ton reaction [19, 20]. Tovbin et al reported that IVIR in
HD patients induced an increase in the level of protein
oxidation products, as assessed by AOPP levels, and that
this effect is positively related to the inflammatory state
of patients [21]. They proposed that IVIR and inflam-
mation synergistically induce oxidative stress. However,
the effect of IVIR in HD patients on individual plasma
proteins, especially albumin, the most abundant protein,
has not been extensively investigated. Therefore, the pur-
pose of this study was to determine the effect of iron and
reactive oxygen species on the HPLC profiles of serum al-
bumin in vitro, and then to investigate the effect of IVIR
on the oxidation levels in serum albumin in HD patients.
In the current studies we report on the oxidation of
albumin by HPLC analysis and the carbonyl content of
individual plasma proteins in HD patients with or with-
out IVIR, as well as in healthy subjects. The findings here
show that albumin is oxidized to a greater extent in HD
patients than in healthy subjects, and that the oxidation of
albumin was significantly enhanced in patients receiving
IVIR. Since albumin is the major plasma protein target
for oxidative reactions, HPLC analysis represents a po-
tential assay method for the assessment of oxidative stress
levels in HD patients.
METHODS
Patients
The protocol used in this study was approved by the
institutional review board, and informed consent was ob-
tained from all subjects. Twenty-two stable HD patients
(15 men, 7 women) aged 25 to 87 years, with a dialysis
age ranging between 1 and 9 years, were enrolled in this
study. Eleven age- and gender-matched healthy subjects
were also investigated as a control group. End-stage re-
nal failure was caused by glomerulonephritis (N = 8),
nephrosclerosis (N = 3), diabetic nephropathy (N = 9),
and unknown causes (N = 2). At inclusion, all patients
were on regular bicarbonate hemodialysis therapy (4 to
5 hours three times weekly) using high-flux polysulfone
hollow-fiber dialyzers, and had not received IVIR for the
last three months. All patients were not treated with an-
tioxidants such as vitamin E and C in the three months
before inclusion onto the study. Patients were divided
into two groups. The first group (IVIR group) was ad-
ministered 40 mg of saccharated ferric oxide (Fesin,
Mitsubishi Pharma Co., Ltd., Osaka, Japan) intra-
venously after every dialysis session for four weeks (total
dosage: 480 mg of saccharated ferric oxide). The other
group (no IVIR group) was treated with vehicle (saline)
for four weeks. At the end of the IVIR or vehicle treat-
ment period, blood samples were obtained before the first
dialysis session of the week.
Chromatographic analysis of serum albumin
in hemodialysis patients
HPLC was performed as described by Hayashi et al
[22]. Serum samples obtained from each patient were
immediately frozen and stored at −80◦C until used for
HPLC analysis. HPLC analysis of 5 lL aliquots of each
serum was performed using a Shodex Asahipak ES-502N
column (Showa Denko Co., Ltd., Tokyo, Japan; column
temperature; 35◦C ± 0.5◦C). The HPLC system was com-
posed of an intelligent pump L-6200 equipped with a gra-
dient programmer and an F-1050 fluorescence detector
(Hitachi Co., Ltd., Tokyo, Japan). Elution was performed
by means of a linear gradient with increasing ethanol
concentrations from 0% to 5% for serum in 0.05 mol/L
sodium acetate and 0.40 mol/L sodium sulfate mixture
(pH 4.85) at a flow rate of 1.0 mL/min. From the HPLC
profiles of HSA, the value of each albumin fraction
(f(HMA), f(HNA-1), and f(HNA-2)) was estimated by
dividing the area of each fraction by the total area corre-
sponding to HSA.
Plasma protein carbonyl contents measurement
Plasma protein carbonyl contents were determined by
the method of Climent et al [23].
Western blots
The oxidation of individual plasma proteins was mea-
sured by Western blot analysis as previously described
by Shacter et al [5]. Plasma was diluted to 2 mg/mL of
total protein with phosphate-buffered saline (PBS), and
derivatized with DNP using an OxyBlot Kit (Serolog-
icals Corporation, Norcross, GA, USA). Samples were
diluted to 1 mg/mL of total protein by the addition of an
equal volume of nonreducing sample buffer, and 15 lL
samples were electrophoresed on duplicate SDS-PAGE
gels [24]. Following electrotransfer to a polyvinylidene
difluoride (PVDF) membrane, one blot was stained for
DNP using the OxyBlot Kit reagents. The second blot
was stained with Coomassie brilliant blue G for protein.
Bands were visualized with chemiluminescent chemicals
and captured on film at 10 minutes.
Analysis of blots
Each Western blot included samples from both pa-
tients and healthy subjects so that in all experiments, pa-
tient samples could be compared with equivalent data on
healthy subjects developed under the same conditions.
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Fig. 1. High-performance liquid chromatog-
raphy (HPLC) profile of in vitro–oxidized
serum albumin. HPLC profile of albumin
from a normal subject under basal condition
(A). Serum was incubated with 200 lmol/L
of H2O2 in the presence or absence of 180
lmol/L of saccharated ferric oxide for 1 hour
(B and D) or 24 hours (C and E). Five-
lL aliquots of each serum were analyzed by
HPLC using a Shodex Asahipak ES-502N col-
umn. HMA; mercaptalbumin (reduced form),
HNA-1; nonmercaptalbumin (disulfide form),
HNA-2; nonmercaptalbumin (oxidized form).
For each experiment, the carbonyl density was deter-
mined from the blot with the shortest possible exposure
time required to produce clearly visible bands. DNP and
protein blots were scanned using the same size section
of the blot for each scan. The uniform window size and
analysis box ensured that data were being analyzed con-
sistently from band to band and from blot to blot. Because
the concentration of various plasma proteins differs be-
tween patient groups and healthy subjects, densitometry
data for the area of the DNP blot band were divided by
the densitometry data for the area of the protein blot band
obtained under identical gel loading and electrotransfer
conditions. These data are recorded as DNP area/protein
area and are reported in densitometry units. The mean
for each subject group was calculated from each blot.
Statistics
Statistical significance was evaluated using the two-
tailed, unpaired Student t test for comparisons between
two means, or analysis of variance (ANOVA) analysis
followed by Newman-Keuls method for more than two
means. A value of P < 0.05 was regarded as statistically
significant. Results are reported as mean ± SE.
RESULTS
Oxidation of serum albumin by H2O2 and Fe in vitro
The current study was designed to determine the redox
state of HD patients, and to examine the effect of IVIR on
oxidative stress, especially oxidation of serum albumin, in
HD patients. First of all, we determined the HPLC pro-
file of serum albumin before and after in vitro oxidation
by H2O2 and Fe treatment. HPLC analysis allowed us
to determine the oxidation status of Cys-34 residues in
the albumin. Sera from healthy subjects were incubated
with 200 lmol/L of H2O2 with or without 180 lmol/L of
saccharated ferric oxide for 1 hour or 24 hours, and then
subjected to HPLC analysis as described in the Methods
section. Figure 1 shows typical HPLC profiles of serum
albumin from a healthy volunteer before and after oxi-
dation treatment. Serum albumin is separated into three
peaks by the HPLC column (Fig. 1A). The first peak rep-
resents HMA (reduced form), the second peak, HNA-1
(disulfide form; HNA(Cys) or HNA(Glut)), and the third
peak HNA-2 (oxidized from; HNA(Oxi)). Treatment of
serum with 200 lmol/L of H2O2 for 1 hour resulted in a
slight increase in HNA-1 and almost no change in HNA-2
(Fig. 1B). Twenty-four hours after incubation, HMA was
reduced and both HNA-1 and HNA-2 fractions were fur-
ther increased, indicating the oxidation of Cys-34 residues
in the albumin (Fig. 1C). In the presence of 180 lmol/L
of saccharated ferric oxide, treatment of serum with
200 lmol/L of H2O2 further potentiated the oxidation of
albumin both at 1 and 24 hours (Fig. 1D and E). The ratio
of each albumin fraction to the total albumin (f(HMA),
f(HNA-1), and f(HNA-2)) was calculated, and those data
are summarized in Table 1. As shown in Table 1, incuba-
tion of serum with 200 lmol/L of H2O2 and 10 lg/mL
of saccharated ferric oxide for 24 hours markedly in-
creased f(HNA-1) and f(HNA-2) values when compared
with those with H2O2 treatment alone (P < 0.05). These
results suggest that treatment with saccharated ferric ox-
ide could enhance the oxidation of serum albumin in the
presence of H2O2, and that HPLC analysis of serum albu-
min provides quantitative and qualitative values for the
oxidation status of albumin.
Oxidation of serum albumin in HD patients
Next, we determined the oxidation status of serum
albumin by HPLC analysis from HD patients with or
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Table 1. f(HMA), f(HNA-1), and f(HNA-2) values (%) for reduced and oxidized albumin in serum from normal subjects treated with H2O2 in
the presence or absence of saccharated ferric oxide
Without saccharated ferric oxide With saccharated ferric oxide
0 hr 1 hr 24 hrs 0 hr 1 hr 24 hrs
f(HMA) 69.5 ± 0.2 67.3 ± 0.7 45.9 ± 1.1 69.9 ± 3.5 62.3 ± 0.8 44.9 ± 0.8
H2O2 f(HNA-1) 24.9 ± 0.7 26.6 ± 1.6 35.0 ± 1.4 23.0 ± 0.5 27.7 ± 0.6 45.5 ± 0.4a
(200 l mol/L) f(HNA-2) 5.6 ± 0.9 6.1 ± 1.7 8.5 ± 2.5 7.1 ± 2.0 9.7 ± 0.2 13.6 ± 1.1a
aP < 0.05 as compared with serum treated with H2O2 in the absence of saccharated ferric oxide. Values are expressed as mean ± SE (N = 4).
Table 2. f(HMA), f(HNA-1), and f(HNA-2) values (%) for reduced
and oxidized albumin in serum from normal subjects and patients
without IVIR treated with vehicle or saccharated ferric oxide
Healthy subjects Patients without IVIR
Saccharated Saccharated
Vehicle ferric oxide Vehicle ferric oxide
f(HMA) 66.7 ± 0.7 64.6 ± 0.4 45.4 ± 2.1 36.9 ± 1.0a
f(HNA-1) 27.8 ± 0.6 29.7 ± 0.5 41.3 ± 2.3 43.6 ± 1.6
f(HNA-2) 5.5 ± 0.1 5.6 ± 0.2 13.3 ± 0.6 19.5 ± 1.5a
aP < 0.05 as compared with serum treated with vehicle. Values are expressed
as mean ± SE (N = 7).
without IVIR, as well as from healthy subjects, because
albumin is the most abundant serum protein and has been
shown to be a target of oxidative stress in uremic patients.
Patient profiles of healthy subject group, IVIR group, and
no-IVIR group are summarized in Table 2. Data in the
patients group were obtained after the treatment period.
Parameters for iron status were examined before and af-
ter IVIR. Patient groups did not differ in respect to age,
gender, diabetes/nondiabetes ratio, duration and efficacy
of dialysis, serum albumin, uric acid, and C-reactive pro-
tein (CRP) levels. Serum Fe and TSAT levels in HD pa-
tients with IVIR were slightly, but not significantly, higher
than in those without IVIR, and serum ferritin levels were
significantly increased in IVIR group due to iron admin-
istration (P < 0.05). Figure 2 shows typical HPLC profiles
for serum albumin from healthy subjects (Fig. 2A), HD
patients without IVIR (Fig. 2B), and with IVIR (Fig. 2C).
The ratio of each albumin fraction to the total albu-
min (f(HMA), f(HNA-1), and f(HNA-2)) was calculated
and those data are summarized in Table 3. As shown in
Figure 2 and Table 3, f(HMA) was substantially decreased
and both f(HNA-1) and f(HNA-2) were significantly in-
creased in HD patients compared with healthy subjects
(P < 0.05). IVIR treatment resulted in marked increases
in both f(HNA-1) and f(HNA-2) in HD patients (P <
0.05), while there was no significant change in f(HMA).
These findings suggest that Cys-34 residue in albumin is
highly oxidized in HD patients and that IVIR resulted in
the overoxidation of albumin. In order to determine the
relationship between the redox status of plasma proteins
and the Cys-34 oxidation of serum albumin, as detected
by HPLC, the plasma protein carbonyl contents of these
patients were also determined.
Plasma protein carbonyl contents in HD patients
In most cases, protein oxidation is associated with an
increase in carbonyl content. It is known that an increase
in carbonyl contents reflects the oxidation of Lys, Arg,
or Pro residues in a protein. Plasma protein carbonyl
contents were significantly increased in HD patients, and
IVIR further enhanced the carbonylation of plasma pro-
tein (IVIR: 2.2 ± 0.4 nmol/mg protein, N = 11; no IVIR:
1.0 ± 0.1 nmol/mg protein, N = 11; healthy subjects:
0.4 ± 0.03 nmol/mg protein, N = 11, P < 0.05). We next
determined the carbonyl contents of major plasma pro-
teins separately by Western blot analysis using an anti-
DNP antibody. Figure 3A shows a representative blot and
Figure 3B summarizes results obtained from the multiple
blots. Interestingly, only albumin was significantly oxi-
dized in HD patients, and IVIR increased the albumin
oxidation (P < 0.05). There was no statistically significant
difference in the carbonyl contents of other plasma pro-
teins such as transferrin, immunoglobulin, and fibrinogen
among three groups (healthy subjects, HD patients with-
out IVIR, and HD patients with IVIR). These findings
suggest that the origin of the increase in plasma protein
carbonyl contents in HD patients was largely from an in-
crease in oxidized albumin, and that IVIR substantially
increased plasma protein carbonyl contents by oxidizing
albumin.
Relationship between HPLC profile of albumin
and plasma protein carbonyl content
In order to validate the usefulness of HPLC analy-
sis of serum albumin for the assessment of oxidative
stress in HD patients, we determined the relationship be-
tween plasma protein carbonyl contents and f(HNA-1) or
f(HNA-2) values because plasma protein carbonyl con-
tents are one of the reliable and widely used oxidative
stress markers. As shown in Figure 4, both f(HNA-1) and
f(HNA-2) have strong correlation with plasma protein
carbonyl contents (R = 0.674 and R = 0.724, respectively,
P < 0.01). We also investigated the relationship between
AOPP levels and f(HNA-1) or f(HNA-2) values, and ob-
tained significant correlation (data not shown). These
findings suggest the possibility that f(HNA-2) values can
be useful markers for the evaluation of redox status of
HD patients.
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Fig. 2. High-performance liquid chromatog-
raphy (HPLC) profile of serum albumin from
HD patients with or without intravenous iron
administration (IVIR). Five-lL aliquots of
serum from HD patients with or without
IVIR, and healthy subjects were subjected
to HPLC analysis using a Shodex Asahipak
ES-502N column. A representative tracing of
HPLC profiles of serum albumin from nor-
mal subjects (A). A representative tracing of
HPLC profiles of serum albumin from HD
patients without IVIR (B). A representative
tracing of HPLC profile of serum albumin
from patients treated with IVIR (C).
Table 3. Characteristics of patient group
Patients without IVIR Patients with IVIR
(N = 11) (N = 11)
Healthy subjects
(N = 11) After vehicle Before vehicle After IVIR Before IVIR
Age years 67.7 ± 0.4 68.0 ± 3.7 68.6 ± 5.6
Gender M/F 7/4 8/3 7/4
Duration of dialysis months – 22.4 ± 7.5 22.5 ± 7.1
Diabetes/nondiabetes – 5/6 4/7
Kt/Vurea – 1.46 ± 0.04 1.52 ± 0.08
Albumin g/dL 4.27 ± 0.07 3.73 ± 0.11 3.53 ± 0.14
Uric acid mg/dL 4.79 ± 0.3 8.1 ± 0.6 7.8 ± 0.4
CRP mg/dL 0.15 ± 0.04 0.28 ± 0.06 0.27 ± 0.08
Fe lg/dL 83.82 ± 5.55 47.6 ± 6.5 49.4 ± 5.8 55.4 ± 2.6 45.5 ± 4.4
TSAT % 28.97 ± 2.61 23.0 ± 6.7 21.2 ± 8.7 28.6 ± 6.2 21.0 ± 1.7
Ferritin ng/mL 43.27 ± 4.99 96.9 ± 19.1 102.5 ± 24.3 231.4 ± 55.4a 75.4 ± 16.2
aP < 0.05. Values are expressed as mean ± SE.
DISCUSSION
The current studies demonstrate that serum albumin
is highly oxidized in HD patients, with an increase in the
disulfide form, and that IVIR on these patients signifi-
cantly increased the oxidation status of albumin, as ev-
idenced by a marked increase in the oxidized form. To
our knowledge, this is the first report demonstrating the
effect of IVIR on the oxidation of serum albumin in HD
patients. Plasma is known to contain a wide range of im-
portant antioxidants, including albumin, ascorbate, and
urate. In contrast, the concentrations of superoxide dis-
mutase, reduced glutathione, and catalase, all of which
are known to be important intracellular antioxidants, are
low in the plasma and are not likely to serve as impor-
tant plasma antioxidants [25, 26]. It has previously been
established that certain amino acid residues of proteins
are particularly susceptible to free radical attack [27, 28],
and several studies have confirmed that Cys-34 of serum
albumin is highly accessible to reactive oxygen species
such as H2O2 [29, 30] and carbon-centered free radicals
[31], as well as other oxidizing agents, such as nitric oxide
(NO) [32–34] and peroxynitrite (ONOO−) [29, 35]. In ad-
dition, it has been demonstrated that Cys-34 of oxidized
albumin is further oxidized to sulfenic, sulfinic, or sulfonic
state under stronger H2O2-mediated [29, 30] and anaer-
obic NO–mediated [33] oxidizing conditions. In plasma,
free thiol groups are quantitatively the most important
scavengers of oxidants, and are known to be largely
located on the albumin molecule. Furthermore, we
confirmed the carbonyl formation of plasma albumin, as
previously demonstrated by Himmelfarb et al [3], sug-
gesting that basic amino acid residues in albumin as well
as Cys-34 are also oxidized. Because albumin is the most
abundant plasma protein, it could play a major role as
an antioxidant in plasma at least by thiol oxidation and
carbonyl formation. We recently demonstrated that the
plasma half-life of radiolabelled- and in vitro oxidized-
albumin was substantially decreased in mice, and that the
liver uptake clearance of oxidized albumin was markedly
increased by 11-fold [36]. These findings suggest that
serum albumin might play an important protective role
against reactive free radicals in extracellular fluids via
its oxidation and the subsequent clearance from the sys-
temic circulation by the liver. In this context, we expected
that the characterization of oxidation status of serum al-
bumin might provide useful information regarding the
redox state of the human body, prompting us to examine
the effect of IVIR on the oxidation of albumin. As shown
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Fig. 3. Carbonyl content of major plasma proteins from normal sub-
jects and HD patients with or without intravenous iron administration
(IVIR). Plasma samples from HD patients with or without IVIR were
derivatized with DNP and subjected to duplicate SDS-PAGE gels (A).
Following electrotransfer, one blot was stained with Coomassie bril-
liant blue G for protein (upper blot) and the second blot was stained
for DNP using OxiBlot kit reagents (lower blot). Carbonyl formation
of major plasma proteins (albumin, transferrin, immunoglobulin, and
fibrinogen) were determined as densitometry ratio of DNP area and
protein area, and are reported in densitometry units (B). Values are ex-
pressed as mean ± SE; N = 11 patients per group. ∗P < 0.05 as compared
with plasma from patients without IVIR.
in Figure 1, an HPLC analysis of serum albumin showed a
clear separation of HMA, HNA-1, and HNA-2. In HD pa-
tients, we found that serum albumin is oxidized, leading to
an increase in both f(HNA-1) and f(HNA-2), and that an
increase in f(HNA-2) is associated with IVIR. There was
no significant difference between the non-IVIR group
and IVIR group in several markers that can affect oxida-
tive stress levels, such as dialysis efficiency (Kt/Vurea),
uric acid, CRP, and diabetes. These results suggest that
HPLC analysis has the potential to provide quantitative
as well as qualitative information on the states at oxida-
tion of serum albumin in HD patients. Furthermore, our
findings suggest that IVIR is associated with an increase
in the oxidized albumin, as evidenced by an increase in
f(HNA-2) and plasma protein carbonyl contents.
Cardiovascular diseases continue to be the major cause
of both morbidity and mortality for patients on HD ther-
apy. For HD patients, the annual mortality rate caused
by cardiovascular disorders is approximately 9%, which
is 10- to 20-fold higher than the general population, even
when adjusted for age, sex, race, and the presence or
absence of diabetes [37]. A potential link between
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Fig. 4. Relationship between plasma protein carbonyl content and
f(HNA-1) (A) or f(HNA-2) (B). Plasma protein carbonyl contents and
f(HNA-1) or f(HNA-2) values from normal subjects and HD patients
with or without intravenous iron administration (IVIR) are plotted,
and the line shows linear regression of plasma protein carbonyl content
and f(HNA-1) or f(HNA-2) values (N = 33, R = 0.674 and R = 0.724,
respectively, P < 0.01).
Table 4. f(HMA), f(HNA-1), and f(HNA-2) values (%) for reduced
and oxidized albumin in sera from healthy subjects and HD patients
with or without IVIR
Healthy Patients without Patients with
subjects IVIR IVIR
(N = 11) (N = 11) (N = 11)
f(HMA) 68.1 ± 2.12 58.5 ± 7.37a 50.3 ± 7.25a
f(HNA-1) 28.9 ± 1.76 36.0 ± 6.03a 41.7 ± 6.27a,b
f(HNA-2) 2.99 ± 0.40 5.46 ± 1.50a 8.7 ± 2.22a,b
Values are expressed as mean ± SE.
aP < 0.05 as compared with sera from healthy subjects.
bP < 0.05 as compared with sera from patients without IVIR.
inflammation, hypoalbuminemia, and subsequent cardio-
vascular risk in HD patients may be through the process
of oxidative stress. Although Fe2+ is known to be a pow-
erful source of hydroxyl radicals through the Fenton reac-
tion, the majority of HD patients receive IVIR for anemia
correction. Because iron loading markedly alters the an-
tioxidant system [38], and because uremic patients have
numerous defects in antioxidant defense that are unre-
lated to iron, iron toxicity could amplify these defects,
and IVIR in HD patients may represent a specific condi-
tion that enhances iron toxicity through the generation of
oxidative stress. This hypothesis is also supported by the
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recent study showing that intensive IVIR was an inde-
pendent factor associated with a decreased survival and
higher rates of hospitalization for HD patients [39]. HD
patients have relatively lower serum albumin levels for
several reasons, including malnutrition. Given the fact
that albumin is a major antioxidant in the extracellular
fluid, a decrease in serum albumin levels in these patients
would contribute to the high incidence of cardiovascu-
lar events that are frequently associated with an increase
in oxidative stress. Significance of oxidized serum albu-
min in HD patients in the progression of cardiovascular
diseases is not fully determined. However, in the case of
HD patients, it has been demonstrated that the carotid
artery intima-media thickness is associated with the level
of plasma advanced oxidation protein products (AOPP),
serum ferritin, and the annual intravenous iron dose ad-
ministered [40], and that AOPP is mostly due to albumin
[41]. These findings suggest the possibility that oxidized
albumin in HD patients might play a pathogenic role in
the progression of atherosclerosis. A study by Boaz et al
has suggested that antioxidant therapy may lessen cardio-
vascular complications in end-stage renal disease patients
[42], suggesting the importance of evaluating oxidative
stress and the appropriate antioxidant therapy in HD pa-
tients, especially in patients who are receiving IVIR. The
coadministration of antioxidants such as vitamin E with
IVIR has been shown to be effective in reducing oxida-
tive stress in HD patients [43]. HPLC analysis of serum
albumin represents a potentially useful marker for the
qualitative and quantitative evaluation of oxidative stress
in HD patients, as well as for the assessment of the effect
of antioxidant therapy.
CONCLUSION
The findings here suggest that IVIR is associated with
an increase in the oxidative state of serum albumin, and
that the HPLC analysis of serum albumin would be a use-
ful marker for the quantitative and qualitative evaluation
of oxidative stress in HD patients.
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